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Schizophrenia is a psychiatric disorder characterized by 
an impaired judgment of reality, such as delusions and 
hallucinations1. Approximately 20 million people 
worldwide have schizophrenia2. Riset Kesehatan Dasar 
(RISKESDAS, Basic Health Research) Data from Ministry 
of Health Republic of Indonesia3 in 2018 showed the 
prevalence of schizophrenia/psychosis in Indonesia is 
6.7 per 1000 households.  In Indonesia, the prevalence 
increased from 1.7% in 2003 to 7% in 2013.  
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Schizophrenia is a psychiatric disorder that requires antipsychotics 
therapy. Antipsychotics cause many side effects, including orthostatic 
hypotension. The study aimed to describe the incidence of orthostatic 
hypotensive side effects experiences by schizophrenia patients at the 
Sambang Lihum Mental Health Hospital, South Kalimantan. This 
research was observational description research with data sampling 
by medical records. This research was conducted to 300 medical 
records of patient’s period January-December 2018 which received 
antipsychotics medication and data analyzed by univariate analysis. 
The results showed the number of patients who experienced 
orthostatic hypotension was 98 patients (32.67%) and no experienced 
were 202 patients (67.33%). Incidence of orthostatic hypotension in 
haloperidol 54.35% (N=46); trifluoperazine 100% (N=1); clozapine 
84.62% (N=13); olanzapine 100% (N=1); haloperidol-chlorpromazine 
27.27% (N=11); haloperidol-haloperidol 42.86% (N=7); clozapine-
risperidone 16.67% (N=6); haloperidol-clozapine 15.05% (N=93); 
haloperidol-olanzapine 50% (N=2); haloperidol-risperidone 31.82% 
(N=22); trifluoperazine-olanzapine 100% (N=1); trifluoperazine-
clozapine 22.22% (N=9); trifluoperazine-risperidone 5.56% (N=18); 
chlorpromazine-haloperidol-haloperidol 33.3% (N=3); 
chlorpromazine-haloperidol-trifluoperazine 100% (N=3); haloperidol-
trifluoperazine-chlorpromazine 100% (N=1); chlorpromazine-
haloperidol-clozapine 42.86% (N=7); chlorpromazine-trifluoperazine-
clozapine 100% (N=1); chlorpromazine-trifluoperazine-olanzapine 
100% (N=1); chlorpromazine-trifluoperazine-risperidone 50% (N=2); 
trifluoperazine-haloperidol-risperidone 100% (N=4); haloperidol-
trifluoperazine-risperidone 100% (N=1); trifluoperazine-haloperidol-
clozapine 40% (N=5); haloperidol-haloperidol-clozapine 80% (N=5); 
clozapine-risperidone-trifluoperazine 100% (N=4); risperidone-
clozapine-haloperidol 20% (N=10). The conclusion from this study 
was the percentage of orthostatic hypotension on schizophrenia 
patients at the Sambang Lihum Mental Health Hospital was 32.67% 
(N=98). 
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Schizophrenia is a mental illness characterized by several 
symptoms, such as positive, negative, and cognitive 
symptoms. To establish a diagnosis of schizophrenia in a 
patient, several criteria are needed, such as two or more 
positive, disorganized speech or behavior, or negative 
symptoms that have occurred for at least six months, 
with at least one of them being positive symptoms or 
irregular speech4. The pathomechanism of schizophrenia 
is not fully understood, so that treatment with current 
antipsychotics still has different effects in each case of 
schizophrenic patients5. 
Antipsychotic is the primary therapy for schizophrenia. 
Schizophrenia requires antipsychotic therapy for a long 
time to cause side effects in treatment therapy6. One of the 
side effects of antipsychotics is orthostatic hypotension7. 
Orthostatic hypotension is characterized by a decrease in 
systolic blood pressure of at least 20 mmHg or a decrease 
in diastolic blood pressure of at least 10 mmHg from 
normal values for three minutes in a standing position8.  
Antipsychotics affect cholinergic, α-adrenergic, 
histaminergic, and serotonergic receptors9. Therefore, the 
antipsychotic potential to cause side effects such as 
orthostatic hypotension, especially antipsychotics that act 
as α-blockers. Neurogenic and non-neurogenic factors 
can cause orthostatic hypotension. Drugs, especially 
antipsychotics, are the most common cause of non-
neurogenic orthostatic hypotension10. Antipsychotics 
that can cause orthostatic hypotension are considered 
antipsychotics that act on α-1 postsynaptic receptors like 
typical antipsychotics11; however, supporting data is still 
very limited. 
Sambang Lihum Mental Health Hospital is a regional 
hospital in South Kalimantan, Indonesia, that provides 
psychiatric and non-psychiatric services. Based on data, 
schizophrenia is the first rank of the top 10 most diseases 
in Sambang Lihum Mental Health. A previous study was 
conducted at the Sambang Lihum Mental Health stated 
that the side effect of orthostatic hypotension was the 
second highest after extrapyramidal syndrome12. 
Therefore, this study was conducted to assess the 
incidence of orthostatic hypotension in the use of 
antipsychotics. The study aimed to describe the incidence 
of orthostatic hypotension in schizophrenia patients 
given antipsychotic therapy at the Psychiatric Hospital of 
Sambang Lihum, South Kalimantan. 
 
MATERIALS AND METHODS 
Materials 
The research instrument used the medical records of 
patients with schizophrenia from Sambang Lihum 
Mental Health Hospital. The data were collected using 
the data collection sheet. 
Methods 
The research was conducted in Sambang Lihum Mental 
Health Hospital, South Kalimantan, Indonesia. The 
research was approved by the Faculty of Medicine's 
ethics and law committee, Universitas Lambung 
Mangkurat, Indonesia, with No. 212/KEPK-FK 
UNLAM/EC/VI/2019. The study belongs to 
observational research with a retrospective approach. 
The population included patients with schizophrenia. 
Inclusion criteria were inpatients diagnosed with 
schizophrenia in Sambang Lihum Mental Health 
Hospital and had a complete medical record (patient's 
characteristic, antipsychotic therapy history). The 
exclusion criteria included inpatients still in intensive care 
(unstable condition) and forced discharged status. 
The data were collected by purposive sampling, and 300 
medical records were fulfilled inclusion and exclusion 
criteria. The collected data from the medical records 
(January to December 2018) were in the form of patients' 
identities such as gender, age, education, occupation, 
marital status, the use of antipsychotics, and orthostatic 
hypotension incidence. The data were analyzed using 
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univariate analysis. The characteristics of patients, use of 
antipsychotics, and orthostatic hypotension incidence 
were presented in frequency and percentage tables. 
 
RESULTS AND DISCUSSION 
The population of inpatient schizophrenia was 1345 
patients. Furthermore, the calculation of the number of 
samples (The Hosmer-Lemeshow test) obtained a 
minimum sample size of 298 patients. Based on the 
inclusion and exclusion criteria, 300 medical records were 
selected and analyzed. Demographic data from all 
selected patients were presented in Table I. The result 
showed that most patients were within the age group of 
17-40 years. Age was an important factor in the onset of 
schizophrenia since it most often occurred at the end of 
adolescence or adulthood. At the productive age (17-40 
years), a person must be responsible for his life to survive 
economically and socially13. Some people could 
experience stress due to the burden of responsibility. This 
was triggered the emergence of stress conditions in a 
person14. The onset of schizophrenia in men is earlier than 
in women. The onset of schizophrenia in women is 3-5 
years slower than in men. Women have two peaks of 
onset, in the age range of 25-30 years and >45 years, while 
men are peak for onset in the age range of 21-25 years 
(<40 years)15. 
In Table I, it could be seen that 78.3% of schizophrenic 
patients were male, and 21.7% were female. The role of 
gonadal hormones such as estrogen can affect the risk of 
schizophrenia. Estrogen is known to provide 
neuroprotective effects so that pathologically women 
have a lower risk of developing schizophrenia than 
men16. Estrogen also has a neuroleptic effect through 
changes in postsynaptic dopaminergic signal 
transduction so that psychotic symptoms mediated by 
dopamine can be inhibited. This will indirectly affect the 
onset and course of schizophrenia in women. In addition 
to this explanation, the etiopathology of schizophrenia is 
also associated with stress factors. Estrogen can protect 
women from the adverse effects of social pressure17. 
Most patients had education at primary and secondary 
levels (Elementary, junior, and high school). One of the 
studies assessed determinants of the onset of 
schizophrenia in outpatients at Prof. HB Saanin Mental 
Health Hospital, Padang, West Sumatra, obtained the 
results from the bivariate analysis that there was no 
significant difference between educational status on the 
onset of schizophrenia and non-schizophrenia (p >0.05). 
Therefore, educational status did not affect the onset of 
schizophrenia, but it depends on when the onset of 
schizophrenia occurred, which resulted in people with 
schizophrenia experiencing problems in continuing 
education18. 
Based on employment status, it was known that most 
patients with schizophrenia did not work. Patients with 
early-onset cause cognitive dysfunction, so that it will 
adversely affect the education undertaken19. Patients 
with schizophrenia that experience schizophrenia for the 
first time at a young age generally result in these sufferers 
dropping out of school, making it difficult to find work 
and failing to build good relationships with others. 
Table I. Patients’ demographic data at Sambang Lihum 





Age ≤40 year 224 74.7 
>40 year 76 25.3 
Total 300 100 
Sex Male 235 78.3 
Female 65 21.7 
Total  300 100 
Education No education 31 10.3 
Elementary, junior, 
and high school 
260 86.7 
University  9 3.0 
Total  300 100 
Occupation No occupation 204 68.0 
Occupied  96 32.0 
Total  300 100 
Marital Status Single 166 55.4 




Total  300 100 
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Schizophrenia also has adverse effects on the patient's life 
journey, including marital problems. Not a few in the end 
cause problems for patients in establishing relationships 
with partners, which impacts divorce20. This was also 
shown in Table I, in which more patients were 
divorced/widowed than those who were still married. 
Psychiatric drugs are ideally selective at specific receptors 
on specific nerve cells in the brain and do not affect other 
receptors or neurons. However, this ideal condition has 
not been found in antipsychotics. Several factors cause 
this non-ideal condition21. First, many molecules 
specifically bind to more than one receptor. For example, 
some antipsychotics bind to postsynaptic dopamine 
receptors and acetylcholine muscarinic receptors, 
resulting in side effects such as memory impairment, 
blurred vision, and constipation22. 
The second problem is that those specific drug molecules 
can bind to dopamine receptors in the limbic system or 
basal ganglia. The effect produced when it binds to 
dopamine receptors in the limbic system will produce the 
desired antipsychotic effect. Meanwhile, if these 
molecules bind to dopamine receptors in the basal 
ganglia, and extrapyramidal side effects will appear in 
the form of tremors. Such drug molecules cannot be sent 
to just one part of the brain and absorbed there but 
instead distributed to different regions of the brain23. The 
third problem is that, among the receptor classes, many 
subtypes have been identified, and drug molecules 
usually not only interact with one subtype but can also 
bind with other subtypes. For example, it is known that 
there are approximately 14 subtypes of serotonin 
receptors, so drugs that work to increase brain serotonin 
levels will have many effects because some serotonin 
receptors are inhibitory and some are excitatory24. 
Antipsychotics from either class can be used alone or 
with other psychotropic drugs, such as mood stabilizers 
or antidepressants. In some patients, especially those 
with schizophrenia, a combination of more than one 
antipsychotic drug may be needed to help control 
symptoms. However, this could pose additional risks for 
the patient, which must be taken into account25. Based on 
Table II, it was known that the most used treatment for 
schizophrenic patients was the combination (75.67%), 
whereas the monotherapy was 11.3%. 
Table II. Number of antipsychotics used at Sambang Lihum 






Haloperidol 46 15.33 
Trifluoperazine 1 0.33 
Clozapine 13 4.33 
Olanzapine 1 0.33 
Risperidone 12 4 
Total 73 24.33 
Two antipsychotics 
Chlorpromazine-trifluoperazine 1 0.33 
Haloperidol-chlorpromazine 11 3.67 
Haloperidol-haloperidol (IV) 7 2.33 
Clozapine-risperidone 6 2 
Chlorpromazine-risperidone 3 1 
Haloperidol-clozapine 93 31 
Haloperidol-olanzapine 2 0.67 
Haloperidol-risperidone 22 7.33 
Trifluoperazine-clozapine 9 3 
Trifluoperazine-olanzapine 1 0.33 
Trifluoperazine-risperidone 18 6 




























Trifluoperazine-haloperidol-clozapine 5 1.67 
trifluoperazine-haloperidol-olanzapine 1 0.33 
Clozapine-risperidone-chlorpromazine 1 0.33 
Clozapine-risperidone-trifluoperazine 4 1.33 
Risperidone-clozapine-haloperidol 10 3.33 








Total 2 0.66 
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Most psychopharmaceutical drugs play a role in the 
neurotransmitters, including serotonin, norepinephrine, 
dopamine, acetylcholine, glutamate, and GABA. These 
six neurotransmitters are the central target systems for 
psychotropic drugs26. It is known that the brain has 
natural neurotransmitters; for example, the brain makes 
its morphine, known as β-endorphin. The brain also 
makes its antidepressants, its anxiolytics, and even its 
hallucinogens. Therefore, drugs often mimic the brain's 
natural neurotransmitters27. Initially, it was thought that 
each neuron uses only one neurotransmitter to transmit 
information and uses the same neurotransmitter across 
all its synapses. However, it is known that many neurons 
use more than one neurotransmitter at a single synapse. 
Besides, the input to each neuron at various locations also 
involves many neurotransmitters. This is the basis for 
combining drugs to simultaneously modify several 
neurotransmitters in mental disorders, such as 
schizophrenia28. 
The range of antipsychotic drugs available is very wide, 
and their effectiveness can also vary from individual to 
individual. Besides, not all patients respond fully to one 
antipsychotic, and in this situation, a combination of 
antipsychotics is often prescribed. Evidence for the 
benefit of using one or more antipsychotics in 
combination is often unclear. Based on a systematic 
review, it was found that the use of combination therapy 
in schizophrenic patients was no better than 
monotherapy for the patient's clinical response (RR 0.73 
CI 0.64-0.83)29. 
In Figure 1, it could be seen that the use of typical 
antipsychotics by monotherapy was more than the use of 
atypical ones. The use of two antipsychotics could also be 
seen as the combination of typical and atypical 
antipsychotics at most of the other combinations (two 
antipsychotics). Meanwhile, the combination of three 
antipsychotics shows that the combination of two typical 
and one atypical has a more significant percentage than 
the other combinations (three antipsychotics). 
 
Figure 1. Typical and atypical antipsychotics used at Sambang 
Lihum Mental Health Hospital 
 
Typical antipsychotics is another name for the first-
generation antipsychotics (FGA), which has a 
mechanism of action mainly through inhibition of 
dopamine type 2 (D2) receptors located in the central 
nervous system (mesolimbic areas). Besides D2 
antagonism, first-generation antipsychotics affect other 
receptors, such as muscarinic, adrenergic α1, and 
histamine-1. Meanwhile, second-generation 
antipsychotics (SGA), also called atypical antipsychotics, 
work by antagonizing the D2 receptor and the 5-HT2A 
serotonin receptor in the central nervous system. 
Atypical antipsychotics have lower affinity and 
occupancy for dopaminergic receptors. They have a 
higher affinity for 5-HT2A receptors than D2 receptors22.  
There are important differences in side effect profiles 
between typical and atypical. Typical antipsychotics 
have a higher risk of neurological side effects than 
atypical antipsychotics. The neurological side effects 
include tardive dyskinesia, extrapyramidal symptoms, 
dystonia, and others, while atypical antipsychotics have 
an increased risk of metabolic disorders such as 
hyperglycemia, obesity, and dyslipidemia6. 
Figure 2 showed that the incidence of orthostatic 
hypotension occurred in respondents was 32.67% 
(N=98). Antipsychotic drugs often cause side effects, 
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ranging from mild to severe. Each antipsychotic drug has 
different side effects from one another. Some of the side 
effects of administering antipsychotics include metabolic 
disorders, movement disorders, increased sedation, 
sexual dysfunction, postural or orthostatic hypotension, 
cardiac arrhythmias, and death. The use of antipsychotics 
is one of the causes of orthostatic hypotension6. 
 
Figure 2. Percentage of orthostatic hypotension at Sambang 
Lihum Mental Health Hospital 
 
Table III shows that patients who were given typical 
antipsychotics such as haloperidol, trifluoperazine, 
clozapine, and olanzapine experienced side effects of 
orthostatic hypotension. Meanwhile, patients who were 
given risperidone did not find any incidence of 
orthostatic hypotension. In the combination of two 
antipsychotics, chlorpromazine-trifluoperazine and 
chlorpromazine-risperidone, there were no side effects of 
orthostatic hypotension, whereas, in other combinations, 
orthostatic hypotension was found. The combination of 
three antipsychotics, chlorpromazine-haloperidol-
risperidone, trifluoperazine-haloperidol-olanzapine, and 
clozapine-risperidone-chlorpromazine did not occur 
orthostatic hypotension, whereas, in other combinations, 
there were side effects of orthostatic hypotension. 
Furthermore, the combination of four antipsychotics did 
not occur side effects of orthostatic hypotension. Based on 
Table III, it could be seen that patients who were given 
either haloperidol or clozapine monotherapy or in 
combination experienced orthostatic hypotension. The 
side effects of orthostatic hypotension occurred both in 
the typical and atypical antipsychotics groups. 
Table II. Incidence of orthostatic hypotension at Sambang 










Haloperidol 46 25 54.35 
Trifluoperazine 1 1 100 
Clozapine 13 11 84.62 
Olanzapine 1 1 100 




1 0 0 
Chlorpromazine-
Risperidone 
3 0 0 
Haloperidol-
Chlorpromazine 
11 3 27.27 
Haloperidol-Haloperidol 7 3 42.86 
Clozapine-Risperidone 6 1 16.67 
Haloperidol-Clozapine 93 14 15.05 
Haloperidol-Olanzapine 2 1 50 
Haloperidol-Risperidone 22 7 31.82 
Trifluoperazine-Clozapine 9 2 22.22 
Trifluoperazine-
Olanzapine 
1 1 100 
Trifluoperazine-
Risperidone 








3 3 100 
Chlorpromazine-
Haloperidol-Risperidone 




1 1 100 
Chlorpromazine-
Haloperidol-Clozapine 
7 3 42.86 
Chlorpromazine-
Trifluoperazine-Clozapine 








2 1 50 
Trifluoperazine-
Haloperidol-Risperidone 
4 4 100 
Trifluoperazine-
Haloperidol-Clozapine 
5 2 40 
Trifluoperazine-
Haloperidol-Olanzapine 
1 0 0 
Haloperidol-Haloperidol-
Clozapine 
5 4 80 
Clozapine-Risperidone-
Trifluoperazine 
4 4 100 
Clozapine-Risperidone-
Chlorpromazine 
1 0 0 
Risperidone-Clozapine-
Haloperidol 





1 0 0 
Haloperidol-Risperidone-
Clozapine-Olanzapine 
1 0 0 
Total 300 98 32.67 
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Most antipsychotics are dopamine D2 receptor 
antagonists, and an antipsychotic effect is mediated by 
mesolimbic D2 dopaminergic receptor blockade 
mechanisms22. However, some other antipsychotics also 
affect other receptors such as serotonin 5-HT2 receptors, 
muscarinic receptors (M2), and α-adrenoceptors, 
especially α1-adrenoceptors9. Based on in vivo and in vitro 
studies conducted on Wistar strain rats, it was concluded 
that α1-adrenoceptor plays a significant role in the 
mechanism of the effect of orthostatic hypotension. 
However, it has not been able to explain whether the 
same thing happens in humans, so further research is 
needed30.  
Antipsychotics of the typical and atypical classes tend to 
cause orthostatic hypotension, which is highly 
dependent on the degree of α1-adrenoceptor 
antagonism. This was especially the case in the low 
potency typical antipsychotic group and atypical, i.e., 
clozapine. Clozapine was reported as atypical 
antipsychotics that are most commonly associated with 
orthostatic hypotension. In addition, this can also occur 
with risperidone and quetiapine, especially with fast 
titrations. Side effects of orthostatic hypotension are 
reported to be more frequent in some patient conditions, 
such as elderly patients at risk of falls, patients with 
cardiovascular disease, and patients receiving 
antihypertensive therapy. Therefore, it is necessary to 
manage the dosage carefully to tolerate the side effects. In 
addition, it is advisable to make appropriate treatment 
options, including reducing or splitting the dose or 
switching to drugs with lower antiadrenergic effects5.  
The clinical study “CATIE” (Clinical Antipsychotic Trials 
of Intervention Effectiveness) aims to compare the 
effectiveness and tolerability of atypical antipsychotics 
with typical antipsychotics. The results showed that two 
atypical antipsychotics had the highest orthostatic 
hypotension side effects compared to other 
antipsychotics: clozapine by 24% and quetiapine by 27%. 
This is because both have a high affinity for α1-
adrenoceptor31. Some atypical antipsychotics that also 
have the potential to cause orthostatic hypotension 
include aripiprazole, olanzapine, paliperidone, 
asenapine, iloperidone, risperidone, and ziprasidone. 
This is strongly suspected to be caused by inhibition of 
the α1-adrenoceptor and the anticholinergic effect of 
these antipsychotic drugs. Stimulation of α1-
adrenoceptors causes vascular vasoconstriction, so when 
these receptors are inhibited, it causes vasodilation. 
Vasodilation resulting in a decrease in blood pressure32. 
 
CONCLUSION 
The incidence of orthostatic hypotension side effects in 
patients with schizophrenia at Sambang Lihum Mental 
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